+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Aspergillosis Drugs Market 2020-2024- Product Image
Global Aspergillosis Drugs Market 2020-2024- Product Image

Global Aspergillosis Drugs Market 2020-2024

  • ID: 5205130
  • Report
  • November 2020
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • Abbott Laboratories
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mayne Pharma Group Ltd.
  • Merck & Co. Inc.
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Aspergillosis Drugs Market 2020-2024

The publisher has been monitoring the aspergillosis drugs market and it is poised to grow by $ 658.48 mn during 2020-2024 progressing at a CAGR of 4% during the forecast period. The reports on aspergillosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing awareness of aspergillosis, special regulatory designations, and high risk factors for aspergillosis. In addition, increasing awareness of aspergillosis is anticipated to boost the growth of the market as well.

The aspergillosis drugs market analysis includes the product segment and geographical landscapes.

The aspergillosis drugs market is segmented as below:

By Product
  • Triazoles
  • Other therapeutics
By Geographical Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the use of antifungal combinations as one of the prime reasons driving the aspergillosis drugs market growth during the next few years. Also, a strong pipeline and funding for research on aspergillosis will lead to sizable demand in the market.

The aspergillosis drugs market covers the following areas:
  • Aspergillosis drugs market sizing
  • Aspergillosis drugs market forecast
  • Aspergillosis drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading aspergillosis drugs market vendors that include Abbott Laboratories, Gilead Sciences Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Mayne Pharma Group Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, and Pfizer Inc.. Also, the aspergillosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mayne Pharma Group Ltd.
  • Merck & Co. Inc.
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • Triazoles - Market size and forecast 2019-2024
  • Other therapeutics - Market size and forecast 2019-2024
  • Market opportunity by Product
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mayne Pharma Group Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
Exhibit
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2019 - 2024 ($ million)
  • Global market: Year-over-year growth 2019 - 2024 (%)
  • Five forces analysis 2019 & 2024
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2019
  • Product - Market share 2019-2024 (%)
  • Comparison by Product
  • Triazoles - Market size and forecast 2019-2024 ($ million)
  • Triazoles - Year-over-year growth 2019-2024 (%)
  • Other therapeutics - Market size and forecast 2019-2024 ($ million)
  • Other therapeutics - Year-over-year growth 2019-2024 (%)
  • Market opportunity by Product
  • Customer landscape
  • Market share by geography 2019-2024 (%)
  • Geographic comparison
  • North America - Market size and forecast 2019-2024 ($ million)
  • North America - Year-over-year growth 2019-2024 (%)
  • Europe - Market size and forecast 2019-2024 ($ million)
  • Europe - Year-over-year growth 2019-2024 (%)
  • Asia - Market size and forecast 2019-2024 ($ million)
  • Asia - Year-over-year growth 2019-2024 (%)
  • ROW - Market size and forecast 2019-2024 ($ million)
  • ROW - Year-over-year growth 2019-2024 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Key customers
  • Abbott Laboratories - Segment focus
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Product and service
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Key customers
  • Gilead Sciences Inc. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product and service
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • Glenmark Pharmaceuticals Ltd. - Key customers
  • Glenmark Pharmaceuticals Ltd. - Segment focus
  • Johnson & Johnson - Overview
  • Johnson & Johnson - Business segments
  • Johnson & Johnson - Key offerings
  • Johnson & Johnson - Key customers
  • Johnson & Johnson - Segment focus
  • Mayne Pharma Group Ltd. - Overview
  • Mayne Pharma Group Ltd. - Business segments
  • Mayne Pharma Group Ltd. - Key offerings
  • Mayne Pharma Group Ltd. - Key customers
  • Mayne Pharma Group Ltd. - Segment focus
  • Merck & Co. Inc. - Overview
  • Merck & Co. Inc. - Business segments
  • Merck & Co. Inc. - Key offerings
  • Merck & Co. Inc. - Key customers
  • Merck & Co. Inc. - Segment focus
  • Mylan NV - Overview
  • Mylan NV - Business segments
  • Mylan NV - Key offerings
  • Mylan NV - Key customers
  • Mylan NV - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mayne Pharma Group Ltd.
  • Merck & Co. Inc.
The publisher recognizes the following companies as the key players in the global aspergillosis drugs market: Abbott Laboratories, Gilead Sciences Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Mayne Pharma Group Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the use of antifungal combinations.'

According to the report, one of the major drivers for this market is the increasing awareness of aspergillosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mayne Pharma Group Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll